Publications by authors named "Alexis A Guernet"
Article Synopsis
- Osimertinib is a third-generation EGFR inhibitor preferred for treating mutant lung cancer, but patients develop resistance over time.
- Resistance is mainly caused by secondary mutations like C797S or L718V/Q in lung cancer models.
- Therapeutic testing shows that erlotinib and afatinib can effectively treat certain resistant tumors, and combining osimertinib with erlotinib may help prevent the development of these mutations.
